

Please try another search
Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company’s lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Punit S. Dhillon | 42 | 2018 | Executive Chairman, President, CEO & Secretary |
Praveen Tyle | 62 | 2021 | Independent Director |
Margaret R. Dalesandro | 75 | 2020 | Independent Director |
Sukhwinder S. Rai | 53 | 2022 | Director |
Deborah Charych | 58 | 2023 | Independent Director |
Andrew James Schwab | 52 | 2023 | Director |
Paul A. Grayson | - | 2023 | Director |
Robert Ritch | - | - | Member of Clinical Advisory Board |
Jeffrey Goldberg | - | - | Member of Clinical Advisory Board |
Keith W. Ward | 53 | 2021 | Independent Director |
Eduardo Munoz | - | 2021 | Member of Scientific Advisory Board |
Louis R. Pasquale | - | - | Member of Clinical Advisory Board |
Giovanni Appendino | - | 2021 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review